New therapies in development for autoimmune diseases: their rationale for combination treatmentSTRAND, V.Springer seminars in immunopathology. 2001, Vol 23, Num 1-2, pp 43-61, issn 0344-4325Article

OMERACT II : the biologics perspectiveSTRAND, V.Journal of rheumatology. 1995, Vol 22, Num 7, pp 1415-1417, issn 0315-162XConference Paper

ADVANCES IN THE DIAGNOSIS AND CONCEPT OF SJOEGREN'S SYNDROME (AUTOIMMUNE EXOCRINOPATHY)STRAND V; TALAL N.1979; BULL. RHEUM. DIS.; ISSN 0007-5248; USA; DA. 1979-1980; VOL. 30; NO 9; 7 P.; BIBL. 82 REF.Serial Issue

The influence of ventilation systems on water depth penetration of emergent macrophytesSTRAND, V. Vretare.Freshwater biology (Print). 2002, Vol 47, Num 6, pp 1097-1105, issn 0046-5070, 9 p.Article

Mid-phase treatment with mothers in incest familiesSTRAND, V. C.Clinical social work journal. 1991, Vol 19, Num 4, pp 377-389, issn 0091-1674Article

The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials databaseSCOTT, D. L; STRAND, V.Rheumatology (Oxford. Print). 2002, Vol 41, Num 8, pp 899-909, issn 1462-0324Article

Health care utilization in patients with spondyloarthropathiesSINGH, J. A; STRAND, V.Rheumatology (Oxford. Print). 2009, Vol 48, Num 3, pp 272-276, issn 1462-0324, 5 p.Article

Biologic agents in autoimmune diseasesKEYSTONE, E. C; STRAND, V.Journal of rheumatology. 1996, Vol 23, Num 4, pp 743-746, issn 0315-162XArticle

American College of Rheumatology Hybrid Analysis of Certolizumab Pegol Plus Methotrexate in Patients With Active Rheumatoid Arthritis: Data From a 52-Week Phase III TrialVAN VOLLENHOVEN, R. F; FELSON, D; STRAND, V et al.Arthritis care and research. 2011, Vol 63, Num 1, pp 128-134, issn 0893-7524, 7 p.Article

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD studyFLEISCHMANN, R; VENCOVSKY, J; VAN VOLLENHOVEN, R. F et al.Annals of the rheumatic diseases. 2009, Vol 68, Num 6, pp 805-811, issn 0003-4967, 7 p.Article

How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis : A surveyMAETZEL, A; BOMBARDIER, C; STRAND, V et al.Journal of rheumatology. 1998, Vol 25, Num 12, pp 2331-2338, issn 0315-162XArticle

A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritisOLSEN, N. J; BROOKS, R. H; FOX, D. A et al.Arthritis and rheumatism. 1996, Vol 39, Num 7, pp 1102-1108, issn 0004-3591Article

Immunologic assessment during treatment of rheumatoid arthritis with anti-CD5 immunoconjugateCANNON, G. W; MARBLE, D. A; GRIFFITHS, M. M et al.Journal of rheumatology. 1995, Vol 22, Num 2, pp 207-213, issn 0315-162XArticle

Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis : results of two phase II studiesSTRAND, V; LIPSKY, P. E; CANNON, G. W et al.Arthritis and rheumatism. 1993, Vol 36, Num 5, pp 620-630, issn 0004-3591Article

Natural killing activity in Sjögren's syndromeMIYASAKA, N; SEAMAN, W; BAKSHI, A et al.Arthritis and rheumatism. 1983, Vol 26, Num 28, pp 953-960, issn 0004-3591Article

Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid® birch pollen extract: a randomized, double-blind, placebo-controlled studyHÖIBY, A.-S; STRAND, V; ROBINSON, D. S et al.Clinical and experimental allergy (Print). 2010, Vol 40, Num 7, pp 1062-1070, issn 0954-7894, 9 p.Article

A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic goutTAYLOR, W. J; SCHUMACHER, H. R; VAZQUEZ MELLADO, J et al.Annals of the rheumatic diseases. 2008, Vol 67, Num 6, pp 888-891, issn 0003-4967, 4 p.Article

Longer term benefits of treating rheumatoid arthritis: Assessment of radiographic damage and physical function in clinical trialsSTRAND, V.Clinical and experimental rheumatology (Testo stampato). 2004, Vol 22, Num 5, pp 57-64, issn 0392-856X, 8 p., SUP35Article

Low dose glucocorticoids in early rheumatoid arthritisSTRAND, V; SIMON, L. S.Clinical and experimental rheumatology (Testo stampato). 2003, Vol 21, Num 5, pp S186-S190, issn 0392-856X, SUP31Article

Ambient level of NO₂ augments the inflammatory response to inhaled allergen in asthmaticsBARCK, C; SANDSTRÖM, T; LUNDAHL, J et al.Respiratory medicine. 2002, Vol 96, Num 11, pp 907-917, issn 0954-6111Article

Imaging in rheumatoid arthritis : Results of group discussions : Part 3: Rheumatoid Arthritis: ResponseMOLENAAR, E. T. H; BOERS, M; LASSERE, M et al.Journal of rheumatology. 1999, Vol 26, Num 3, pp 749-751, issn 0315-162XConference Paper

Differential patterns of response in patients with rheumatoid arthritis following administration of an anti-CD 5 immunoconjugateSTRAND, V; LEE, M. L.Clinical and experimental rheumatology (Testo stampato). 1993, Vol 11, pp S161-S163, issn 0392-856X, SUP8Conference Paper

The emerging role of biologics in rheumatic diseaseSTRAND, V.Journal of rheumatology. 1992, Vol 19, pp 40-45, issn 0315-162X, SUP33Conference Paper

The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair^®) treatmentJOHANSSON, S. G. O; NOPP, A; ÖMAN, H et al.Allergy (Copenhagen). 2009, Vol 64, Num 10, pp 1472-1477, issn 0105-4538, 6 p.Article

Reporting Disease Activity in Clinical Trials of Patients With Rheumatoid Arthritis : EULAR/ACR Collaborative RecommendationsALETAHA, D; LANDEWE, R; EMERY, P et al.Arthritis care and research. 2008, Vol 59, Num 10, pp 1371-1377, issn 0893-7524, 7 p.Article